What Is a Chemo Wash for Bladder Cancer?

A chemo wash is the informal name for a procedure in which liquid chemotherapy is placed directly into the bladder through a catheter, left to sit for a set period, and then drained. The medical term is intravesical chemotherapy, and it is one of the most common treatments for bladder cancers that have not grown into the muscle wall. Because the drug bathes the inner lining of the bladder rather than traveling through the bloodstream, it attacks residual cancer cells locally while sparing most of the body from the side effects people associate with traditional chemotherapy. The procedure is simpler than it sounds, but the details around timing, drug choice, and how many rounds you need are worth understanding.

How the Procedure Actually Works

A thin, flexible catheter is threaded through the urethra into the bladder, much like the catheter used during a standard urine test. The chemotherapy drug, mixed into a sterile liquid solution, flows through the catheter and fills the bladder. You then hold the solution inside for a specified dwell time, typically somewhere around one to two hours depending on the drug. During that time, the medication is in direct contact with the bladder’s inner lining, where superficial tumors grow. When the dwell time is up, you simply urinate the solution out, or it is drained through the catheter.

Because the drug stays in the bladder and very little is absorbed into the bloodstream, you avoid most of the system-wide side effects that come with intravenous chemotherapy. There is no hair loss, minimal nausea, and no suppression of blood cell counts in the way that IV chemo causes. The trade-off is that the treatment only reaches the bladder surface, so it is not appropriate for cancers that have invaded deeper layers of the bladder wall or spread elsewhere in the body.

Who Gets a Chemo Wash

Chemo washes are used almost exclusively for non-muscle-invasive bladder cancer, or NMIBC. This category covers tumors confined to the bladder’s inner lining or the thin connective tissue just beneath it. Staging determines the approach: tumors classified as Ta (limited to the innermost layer), T1 (reaching into the connective tissue but not the muscle), and carcinoma in situ (flat, high-grade cells on the surface) all fall under NMIBC.¹ Roughly 75 percent of newly diagnosed bladder cancers are non-muscle-invasive, so this treatment applies to the majority of people who hear the words “bladder cancer.”

After a tumor is removed during a procedure called transurethral resection of a bladder tumor (TURBT), tiny cancer cells can remain scattered across the bladder lining. Accurate assessment of the tumor’s stage and grade is what determines whether a chemo wash alone will suffice or whether additional therapy is needed.² For low-risk tumors, a single instillation of chemotherapy right after surgery is often enough. For intermediate- or high-risk tumors, a single immediate dose is typically followed by additional rounds of either chemotherapy or BCG immunotherapy over the following months.¹

The Most Commonly Used Drugs

Two chemotherapy drugs dominate intravesical treatment: mitomycin C and gemcitabine. Mitomycin C has been the workhorse for decades. It works by damaging the DNA of cancer cells so they cannot divide. Gemcitabine entered bladder cancer treatment more recently and has gained ground because of its side-effect profile.

A meta-analysis of randomized controlled trials comparing gemcitabine to mitomycin C found that patients receiving gemcitabine had a lower recurrence rate and significantly less chemical cystitis, which is the bladder irritation caused by the drug itself.³ Rates of other complications like blood in the urine and skin reactions did not differ meaningfully between the two drugs. This is one reason gemcitabine is increasingly favored, especially for patients who have experienced irritation with mitomycin C. Other drugs, including epirubicin and doxorubicin, are sometimes used but are less common in current practice.

Timing and Schedules

The most time-sensitive chemo wash is the one given right after tumor removal. This immediate instillation, done within hours of the TURBT procedure while you are still in the recovery area, is designed to kill any stray cancer cells before they have a chance to implant on the freshly scraped bladder wall. For low-risk patients, this single dose may be the only treatment needed.

For patients at intermediate risk, the schedule gets longer. A systematic review of randomized trials found that a short, intensive course of instillations over the first three to four months after the initial dose was roughly as effective as treatment stretched over a longer period.⁴ Instillations beyond one year appeared advisable mainly when that immediate post-surgery dose had not been given. In practice, many treatment plans involve weekly instillations for about six weeks, sometimes followed by monthly maintenance sessions.

Whether maintenance therapy is worth it depends on the situation. One study of patients receiving a gemcitabine-docetaxel combination found that those who continued with monthly maintenance instillations had disease-free survival of about 81 percent at one year, compared with roughly 42 percent for those who were simply monitored after the initial course.⁵ By two years, the gap had narrowed and was no longer statistically significant, but the early advantage was real. That pattern helps explain why many urologists recommend at least some period of maintenance for intermediate- and high-risk patients.

How Chemo Washes Compare with BCG

If you look into bladder cancer treatment, you will quickly encounter BCG, an immunotherapy that uses a weakened form of the tuberculosis bacterium to trigger the immune system into attacking cancer cells on the bladder wall. BCG is generally considered the strongest intravesical therapy for intermediate- and high-risk NMIBC. It has been shown to reduce recurrence by up to about two-thirds compared with tumor removal alone.⁶

Chemotherapy instillations also reduce recurrence, but the general view is that they are somewhat less effective than BCG for higher-risk disease. The comparison is more nuanced than it first appears, though. One analysis of nine randomized trials found that the apparent superiority of BCG was partly an artifact of study design: many of the trials enrolled patients who had already failed a prior course of chemotherapy into the chemotherapy arm, biasing results against that group. When the data were limited to patients who had not previously received intravesical drugs, chemotherapy reduced recurrence by 21 to 82 percent compared with BCG, depending on the time point measured.⁷

A practical consideration pushes some patients toward chemotherapy: BCG is hard to tolerate. Intensive BCG maintenance regimens cause enough side effects that a large proportion of patients discontinue treatment before completing the full course.⁶ A randomized trial comparing heated mitomycin C, conventional mitomycin C, and BCG for intermediate-risk NMIBC found no significant difference in recurrence rates among the three arms, but treatment discontinuation due to drug intolerance was significantly higher in the BCG group.⁸ If a patient cannot finish BCG, the theoretical advantage over chemotherapy vanishes. Global BCG shortages in recent years have also made chemotherapy the default option in many clinics simply because BCG was unavailable.

Side Effects and What to Expect

Because the drug stays in the bladder, side effects are concentrated there. The most common complaints are urgency, frequent urination, and a burning sensation during urination (dysuria). These symptoms resemble a urinary tract infection and usually clear up within a day or two after each treatment. Some patients experience fatigue and emotional distress, particularly during intensive treatment schedules. A systematic review covering more than 20,000 patients found that frequent instillations increased urinary symptoms, fatigue, and emotional strain, and that withdrawal rates were high during intensive schedules, reaching up to 90 percent in some studies during the first year of treatment.⁹ That same review noted that reducing the number of instillations could preserve the treatment’s effectiveness while improving quality of life and adherence.

Less common but more serious is chemical cystitis, where the drug itself causes sustained inflammation of the bladder lining. This condition can mimic an infection and is sometimes treated as one before the real cause is identified.¹⁰ As noted earlier, gemcitabine causes less chemical cystitis than mitomycin C, which is one reason it has become a popular alternative. Blood in the urine can occur with either drug. Allergic skin reactions, including rashes on the palms and genitals, have been reported with mitomycin C in particular.

One rare but serious complication is drug extravasation, which happens when the chemotherapy solution leaks through an undetected perforation in the bladder wall made during the TURBT. Because mitomycin C is caustic to surrounding tissue, leakage can cause damage to nearby structures. This is why surgeons exercise caution when deciding whether to give the immediate post-operative instillation: if there is any suspicion that the bladder was perforated during tumor removal, the chemo wash is postponed.

Heat-Enhanced Chemo Washes

One of the more promising refinements to the standard chemo wash involves warming the chemotherapy solution before or during instillation, a technique known as hyperthermic intravesical chemotherapy. The idea is straightforward: heat makes cancer cells more vulnerable to the drug. Laboratory work using bladder cancer tissue models has confirmed the concept, showing that gemcitabine and pirarubicin caused more cell death and significantly reduced cancer cell growth when delivered under heated conditions compared with room temperature.¹¹

Clinical results have been mixed so far. The three-arm trial mentioned earlier, which compared heated mitomycin C with conventional mitomycin C and BCG, found no significant difference in recurrence rates or time to recurrence among the three groups, though the heated group did have a higher rate of non-healing ulcers inside the bladder.⁸ The technique requires specialized equipment that recirculates and heats the drug solution inside the bladder, making it more complex and expensive than a standard instillation. For now, heated chemotherapy is used most often at specialized centers and in clinical trials rather than as a routine first-line approach.

What Happens When BCG Fails

A significant proportion of patients with higher-risk NMIBC are initially treated with BCG, and some of those patients experience cancer recurrence despite completing a full course. This situation, called BCG-unresponsive disease, is one of the more challenging scenarios in bladder cancer management. The standard recommendation at that point is radical cystectomy, or surgical removal of the entire bladder. Many patients, understandably, want to explore options that let them keep their bladder.

Combination intravesical chemotherapy regimens have emerged as an alternative for these patients. The most studied combination is sequential gemcitabine followed by docetaxel. In a study of 102 patients with BCG-unresponsive NMIBC, six-month high-grade recurrence-free survival was 78 percent, dropping to 65 percent at one year and 49 percent at two years. About 20 of those patients eventually underwent radical cystectomy, and six progressed to muscle-invasive disease over the follow-up period.¹² A separate study of the same regimen reported overall survival of 94 percent at two years, with adverse events in about a third of patients but very few requiring treatment discontinuation.¹³

These are encouraging numbers for a population that would otherwise face major surgery, though the recurrence rates make clear that combination chemotherapy is not a permanent fix for everyone. Patients who choose this route need close surveillance, with regular cystoscopies to catch any returning tumors early. If the cancer comes back or progresses into the muscle wall, cystectomy remains the fallback.

Practical Tips That Affect How Well the Treatment Works

A few surprisingly mundane details influence how effective a chemo wash is. Limiting fluid intake for several hours before treatment concentrates the drug inside a smaller volume of urine, keeping the dose in contact with the bladder wall at a higher concentration. Lying in different positions during the dwell time (back, stomach, each side) is sometimes recommended to help the solution reach all surfaces of the bladder, though the evidence for this is more theoretical than proven.

One recommendation that sounds logical but turned out to be ineffective is taking oral sodium bicarbonate before a mitomycin C instillation to make the urine more alkaline. The rationale was that mitomycin C is more stable at a higher pH, so alkalinizing the urine should keep the drug in its active form longer. A study testing this directly found that while sodium bicarbonate did raise urinary pH, the concentration of active mitomycin C in the bladder did not change significantly, and no correlation was found between pH and drug concentration.¹⁴ Some institutions still include alkalinization in their protocols, but the evidence suggests it may not matter.

Surveillance After Treatment

Bladder cancer has one of the highest recurrence rates of any cancer, which is why follow-up after a chemo wash is not optional. The standard surveillance protocol involves regular cystoscopies, where a small camera is inserted into the bladder to look for new tumors. These typically start at three months after treatment and continue at intervals that vary by risk level, sometimes for years.

When recurrence does happen in patients who originally had non-muscle-invasive disease, it is often manageable with repeat tumor removal and additional intravesical therapy rather than major surgery.¹⁵ The picture changes if the cancer returns as muscle-invasive disease, which generally requires cystectomy in patients healthy enough for surgery. The recurring need for surveillance is one of the reasons bladder cancer is among the most expensive cancers to treat over a patient’s lifetime, and it is also why the emotional toll of the disease extends well beyond the initial diagnosis.

Intravesical Chemotherapy in Veterinary Medicine

Bladder cancer affects dogs as well, and veterinary oncologists have borrowed the concept of intravesical chemotherapy from human medicine. Transitional cell carcinoma is the most common bladder cancer in dogs, and it tends to be aggressive. A phase I clinical trial tested intravesical mitomycin C in dogs with localized bladder tumors, using a one-hour dwell time over two consecutive days each month and gradually escalating the drug concentration to determine the maximum tolerated dose.¹⁶ As in humans, systemic absorption of the drug was measured to confirm that the treatment stayed local. The approach remains investigational in veterinary oncology, but the parallel development is a reminder of how broadly applicable the basic principle of local drug delivery is across species.